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Abstract Cardiac myocytes contain functional estrogen recep- 
tors, however, the effect of estrogen on growth-related signaling 
pathways uch as mitogen-activated protein kinases (MAPK) in 
the pathogenesis of cardiac disease is unclear. MAPKs are 
critically involved in regulatory signaling pathways which 
ultimately lead to cardiac hypertrophy. Here we show that 
171]-estradiol (E2) activates extracellular signal-regulated kinase 
(ERKI/2), c-Jun-NHz-terminal protein kinase (JNK) and p38 in 
rat cardiomyocytes in a distinctive pattern. As shown by 
immunoblot analysis and phosphorylation assays, E2 (10 9 M) 
induced a rapid and transient activation of ERKI/2 and a rapid 
but sustained increase of JNK phosphorylation. In contrast, E2 
had only a marginal effect on p38 activation. Furthermore, 
MAPK phosphatase xpression was induced by E2 and E2- 
stimulated expression of endothelial and inducible NO synthase 
was inhibited by PD 98059, an inhibitor of the ERK pathway. 
These novel observations may help to explain the role of estrogen 
in gender-based ifferences found in cardiac disease. 
© 1999 Federation of European Biochemical Societies. 
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1. Introduction 
Cardiac diseases uch as left ventricular hypertrophy reveal 
significant gender-based differences [1,2]. Left ventricular hy- 
pertrophy is an important risk factor for cardiovascular dis- 
ease and is associated with an increased risk of arrhythmias 
and sudden death [3]. Estrogen has been suggested to play a 
major role in the pathogenesis of this process as the incidence 
in women increases after the onset of menopause [4]. Estrogen 
is a member of a large family of steroid hormones that regu- 
late gene transcription i estrogenic target issues upon bind- 
ing to the respective intracellular estrogen receptor (ER) [5,6]. 
To date, two different estrogen receptors, ERc~ and ERr3, have 
been identified and characterized [7,8]. The recently cloned 
ER[3 is highly homologous to the 'classical' ERc~ and has 
been shown to bind estrogens with an affinity similar to 
ERa, and activates expression of genes containing estrogen 
response lements [9]. Cardiac myocytes contain functional 
estrogen receptors of both subtypes that regulate xpression 
of target genes such as NO synthases [10,11]. In addition, 
there are important rapid, therefore termed non-genomic, ef- 
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fects of estrogens on the myocardium [12,13]. These non-ge- 
nomic effects of estrogen in cardiac myocytes are poorly 
understood but may play an important role in the pathogen- 
esis of cardiac hypertrophy and cardiac remodeling after my- 
ocardial infarction. To elucidate the effect of estrogen on sig- 
nal transduction pathways involved in the pathogenesis of 
cardiac disease we investigated the influence of 17J3-estradiol 
on different mitogen-activated protein kinases (MAPKs) in 
cardiomyocytes. MAPKs have been identified as a family of 
protein Ser/Thr-kinases that are rapidly activated by dual 
phosphorylation f their Tyr-Xaa-Thr motif. This phosphor- 
ylation is catalyzed by dual-specific MAPK kinases (MKK/ 
MEK) in response to a wide array of extracellular stimuli [14]. 
Well characterized subfamilies of the MAPK superfamily are 
the extracellular signal-regulated kinases (ERKs) and the two 
stress-responsive MAPK subfamilies, the c-Jun-NH2-terminal 
protein kinase/stress-activated protein kinase (JNK/SAPK) 
and the p38 MAPK [15-17]. Different cell stimuli appear to 
activate distinct MAPKs preferentially. While growth factors 
and some oncogenes are linked to activation of ERK, inflam- 
matory cytokines and cell stress lead to activation of JNK/ 
SAPK and p38 [18]. Here we examined the effect of estrogen 
on MAPK families as mediators of estrogenic effects in adult 
and neonatal rat cardiomyocytes. Inactivation of MAPK is 
mediated, in part, by dephosphorylation f MAPK by dual- 
specificity phosphatases called MAPK phosphatases (MKP) 
that dephosphorylate both threonine and tyrosine residues 
phosphorylated by MEK [19,20]. Since MKP is principally 
regulated at the transcriptional level, we studied the MKP1 
gene expression i  response to estrogen. Finally, we examined 
the influence of MAPK phosphorylation  estrogen-respon- 
sive cardiac genes such as the endothelial and inducible NO 
synthase as cardiac NO production through NO synthases has 
been suggested to play a crucial role in the regulation of 
cardiac muscle function [21,22]. 
2. Materials and methods 
2.1. Materials' 
All chemicals were obtained from Merck (Darmstadt, Germany) if
not otherwise specified. 
2.2. Isolation and culture of adult eardiomyocytes 
Procedures with experimental animals followed the guidelines ofthe 
National Institute of Environmental Health Sciences Animal and Use 
Committee. Cardiomyocytes were isolated after a modified protocol 
by Claycomb and Palazzo [23] from adult female Wistar-Kyoto rats 
weighing 200 350 g. Animals were anesthetized with diethylether and 
heparinized with 2500 units sodium heparin into the vena cava. The 
heart was rapidly dissected and mounted on the cannula of a Lan- 
gendorff perfusion system. Retrograde perfusion was performed ac- 
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cording to the procedure of Powell [24] using a calcium-free perfusion 
buffer containing 128 mM NaC1, 14 mM KC1, 190 ~tM NaH2PO4, 
1 mM Na2HPO4, 1.5 mM MgSO4, 10 mM HEPES, 5.5 mM D-glu- 
cose, 2 mM sodium pyruvate. Enzyme solution consisted of 1.3 mg/ml 
collagenase (0.452 U/mg, Boehringer Mannheim, Germany) and 5 mg/ 
ml albumin, fraction V, fatty acid-free (Boehringer Mannheim). 
Thereafter, total ventricular tissue was chopped, minced into small 
pieces, incubated in 2'7o albumin solution (5 min) and passed through 
a mesh of 250 gm pore size. Cardiac fibroblasts and non-myocytes 
were separated from cardiac myocytes by three consecutive 2% serum 
albumin gradient steps. Freshly isolated cardiomyocytes were counted 
in a Fuchs-Rosenthal chamber and contained 80 85'7, rod-shaped 
ventricular myocytes. Cells were seeded on culture dishes at a density 
of 2× 104 cells/cm 2 and cultured in medium 199 (Gibco, Eggenstein, 
Germany) supplemented with 2 mM carnitine, 5 mM taurine, 5 mM 
creatine, penicillin (100 U/ml) and streptomycin (100 U/ml) (CCT199 
medium, pH 7.4). 
2.3. isolation and culture of neonatal cardiwTo,o~Ttes 
The hearts of 1 2 day old rats were isolated and digested with 10 ml 
of Spinner solution (116 mM NaC1, 5.3 mM KC1, 8 mM NaH2PO4, 
22.6 mM NaHCO3, 10 mM HEPES, 5 mM D-glucose, pH 7.4) con- 
taining 0.1% collagenase (Cytogen, Berlin, Germany) for 10 min at 
37°C in eight consecutive steps as previously described [10]. Cell sus- 
pension was centrifuged at 400 ×g for 5 min and the cell pellet was 
resuspended in 20 ml of Ham's F10 supplemented with 10% horse 
serum (Biochrom, Berlin, Germany) and 10% estrogen-free f tal calf 
serum (FCS: c.c.pro, Neustadt, Germany) and plated on culture 
dishes. After 75 min the medium which contained the cardiomyocyte 
fraction of the digested tissue was removed. Cardiomyocytes were 
counted in a Fuchs-Rosenthal chamber and seeded on culture dishes 
at a density of 2× 104 cells/cm 2. The neonatal cardiomyocyte culture 
contained 90-95% myocytes, as assessed by immunofluorescence 
staining with an antibody against roponin-t (CP05, Dianova, Ham- 
burg, Germany). 
2.4. Treatment of cardiomyo&tes 
Serum-starved cells were treated with 10 9 M 17[3-estradiol in a 
time-dependent fashion for 5, 15, 30, 60, or 120 rain with or without 
10 s M ICI 182.780 (kind gift of Dr. A.E. Wakeling), a specific pure 
antiestrogen [25]. Control cells were incubated with 0.1% (v/v) etha- 
nol, the solvent of 17]3-estradiol. Additional controls were coincu- 
bated with 10 .5 M PD 98059 (Calbiochem, Bad Soden, Germany), 
a selective inhibitor of MAPK kinase (MEKI/2), which catalyzes the 
phosphorylation of MAPK [26], and with SB 203580 (10 -5 M), a 
highly specific inhibitor of p38 kinase [27]. Moreover, a series of 
controls was performed with the stereoisomer 17c~-estradiol, known 
to be biologically ineffective as an estrogen. After stimulation cells 
were rinsed with phosphate-buffered saline and lysed with 500 ~tl 
lysate buffer (50 mM NaCI, 50 mM NaF, 20 mM Tris, 10 mM 
EDTA, 20 mM Na4P2OT, 1 mM Na~VO4, 1% Triton X-100. 1 mM 
PMSF, 10 I.tg/ml antipain, 10 /.tg/ml eupeptin, 10 gg/ml aprotinin). 
Lysates were clarified by centrifugation at 12000×g for 10 min at 
4°C. Protein content was measured with a standard Bradford assay. 
For a positive control we include 20 ng active MAPK (ERK2, New 
England Biolabs, Schwalbach, Germany) to 200 ~1 of control cell 
extract. 
2.5. Western blot analysis 
Total cell lysates (40 gg/lane) of each sample were subjected to 
SDS-PAGE on 7.5% gels for resolution of ERK, JNK and p38 
MAPK. Protein was transferred electrophoretically to a nitrocellulose 
membrane. Equal transfer among lanes was verified by reversible 
staining with Ponceau red. Immunoblotting was performed with a 
monoclonal dual phospho-specific (threonine-202/tyrosine-204) anti-
body directed against he activated ERK1/2 (1:1000; New England 
Biolabs) or a polyclonal phospho-specific antibody against JNK 
(1:500; Santa Cruz, Heidelberg, Germany) or a polyclonal dual phos- 
pho-specific antibody against p38-MAPK (1:500: New England Bio- 
labs). In order to investigate gene expression of MKP1 as well as 
eNOS- and iNOS-specific antibodies against MKP1 (1:500: Santa 
Cruz), iNOS (1:500: Calbiochem) and eNOS (1:500: Calbiochem) 
were used. Detection was performed with the enhanced chemilumines- 
cence technique (ECL; Amersham, Braunschweig, Germany). Densi- 
tometric analysis of immunoblots was performed on an Epson GT 
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8000 scanner with the analysis oftware ScanPak (Biometra, G6ttin- 
gen, Germany). 
2.6. MAPK assay 
In order to determine the activation potential of different MAPKs 
induced by estrogen, we used specific MAPK phosphorylation assays 
(p42/p44 MAPK Assay Kit, JNK/SAPK Assay Kit, p38 MAPK As- 
say Kit; New England Biolabs). Briefly, a monoclonal dual phospho- 
specific antibody directed against he phosphorylated ERK or p38 
protein was used to selectively immunoprecipitate active ERKI/2 
and p38 from total cell lysates. To analyze MAPK activity the result- 
ing immunoprecipitate was incubated in the presence of ATP and 
kinase buffer with an Elk l (Ets [E26 transformation-specific]-like pro- 
tein 1) fusion protein as a substrate for ERK and with ATF-2 fusion 
protein as a substrate for p38. Phosphorylation f the respective sub- 
strate was determined by Western blot analysis using phospho-specific 
antibodies against Elkl or ATF-2. JNK assay was performed using c- 
Jun fusion protein beads containing high affinity binding sites for 
JNK. After binding of JNK to c-Jun fusion protein kinase reaction 
was carried out using c-Jun as substrate. Phosphorylation of c-Jun 
was analyzed by Western blot analysis using a phospho-specific anti- 
body against c-Jun protein. 
2. Z Statistical analysis' 
All experimental data consist of a minimum of at least three inde- 
pendent experiments from three different preparations. All reported 
values are mean + S.E.M. Statistical comparisons were made by Stu- 
dent's t-test. Statistical significance was assumed if a null hypothesis 
could be rejected at the P < 0.05 level. 
3. Results 
To investigate non-genomic effects of estrogen on cardiac 
myocytes we examined the influence of estrogen on different 
MAPKs,  namely ERKI /2,  the JNK/SAPK and p38. Immuno-  
blot analyses with phospho-specific antibodies electively di- 
rected against the activated, phosphorylated MAPK proteins 
were performed. Total cell lysates of cardiac myocytes derived 
from cardiac myocytes from adult female rats (Fig. I A) and 
from neonatal rats (Fig. 1B) revealed only a low level of 
activated 42 kDa and 44 kDa isoforms of ERK1 and ERK2 
in the absence of 17[3-estradiol (E2). Stimulation of cardiac 
myocytes with E2 (10 9 M) for 5 120 min induced a rapid 
and transient increase of phosphorylated ERK1/2 protein. 
ERK phosphorylat ion in adult female cardiomyocytes 
reached a maximum of 3.3 + 0.7-fold after 5 min incubation 
(Fig. 1C). The ERK phosphorylat ion pattern in lysates ob- 
tained in neonatal cardiomyocytes displayed a similar pattern 
and maximal activation occurred after 15 min incubation. 
Cotreatment with the pure ER-specific antagonist ICI 
182.780 (10 -~ M) completely negated the rapid E2-stimulated 
increase in ERK phosphorylat ion at 15 min incubation. 
To further elucidate the effect of E2 on ERK phosphoryl-  
ation in cardiac myocytes we studied the phosphorylat ion of 
ERK substrates uch as Elkl ,  which was determined by an 
ERK phosphorylat ion assay. Incubation with E2 (10 9 M) 
increased phosphorylat ion of the target protein Elkl  by 
ERK1/2 in cardiomyocytes obtained from adult female rats 
(Fig. 2A) as well as from neonatal  rats (Fig. 2B). E2 induced a 
rapid and transient phosphorylat ion of ERK target protein 
demonstrat ing that ERK1/2 phosphorylat ion paralleled 
ERK1/2 activity. Maximum induction of ERK1/2 activity oc- 
curred at 15 min (2.3 +0.2-fold). Cotreatment of cardiomyo- 
cytes with the ER-specific antagonist ICI 182.780 (10 8 M) 
and with a specific MAPK kinasc blocker, PD 98059 (10 .5 M) 
inhibited the E2-mediated phosphorylat ion of the MAPK pro- 
tein and in consequence the phosphorylat ion of Elkl .  
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To extend our previous observations we studied the effect 
of E2 on additional MAPK signaling pathways, namely the 
JNK and p38 pathways. JNK  activity was determined by 
immunoblot analyses of total cell lysates with an antibody 
that specifically recognizes the phosphorylated form of JNK. 
In the absence of E2, the level of JNK  phosphorylation in 
cardiomyocytes from adult female (Fig. 3A) and neonatal rats 
(Fig. 3B) was low. After stimulation with 10 9 M E2 JNK 
phosphorylation increased rapidly and was sustained over 
time. Cotreatment of cardiomyocytes with the specific ER 
antagonist ICI 182.780 (10 8 M) completely inhibited phos- 
phorylation of JNK. These results were confirmed using a 
JNK  assay that specifically measured JNK-induced phosphor- 
ylation of c-Jun. Incubation with E2 (10 -9 M) increased phos- 
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Fig. 2. Time-dependent activation of the ERKI/2 substrate Elk1 by 
E2. ERK1/2 phosphorylation assays show induction of Elkl phos- 
phorylation by E2 in a time-dependent fashion. A monoclonal dual 
phospho-specific antibody was used to immunoprecipitate active 
ERK1/2 from total cellular lysates of adult female (A) and neonatal 
(B) cardiomyocytes incubated in the absence (C) or presence (5 120 
min) of E2 (10 -9 M). The resulting immunoprecipitate was incu- 
bated with an Elkl fusion protein. Phosphorylation of ElM was an- 
alyzed by Western blot analysis using a phospho-Elkl antibody. 
Phosphorylated Elkl protein is detectable in the absence of E2, but 
increases in a time-dependent fashion following E2 treatment. Coin- 
cubation with PD 98059 (PD, 10 5 M) and ICI 182.780 (ICI, 10 8 
M) for 15 rain inhibited ERK1/2-mediated phosphorylation of Elkl. 
Phosphorylated ERK1/2 (+) served as a positive control. Phosphor- 
ylation levels were normalized to IgG to correct for differences in 
protein loading. 
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Fig. 1. Time-dependent activation of ERKI/2 by E2. Cardiomyo- 
cytes from adult female rats (A) and from neonatal rats (B) were 
stimulated with 17[3-estradiol (E2, 10 -9 M) for the indicated time 
periods (5 120 rain). Cell lysates were subjected to SDS-PAGE, im- 
munoblotted with an antibody specifically detecting the phospho- 
rylated ERK1/2, and visualized by a chemiluminescence technique. 
Note that the phosphorylated protein (pERK) is detectable in the 
absence of 1713-estradiol (Control, C), but is more abundant follow- 
ing treatment with E2 in a time-dependent fashion. Coincubation 
with the antiestrogen ICI 182.780 (ICI, 10 -s M) for 15 rain inhib- 
ited the phosphorylation. C: Time course of E2-induced phospho- 
rylation of ERKI/2 in adult rat cardiomyocytes. Relative kinase 
phosphorylation was determined by densitometric analysis of immu- 
noblots. The results are expressed as stimulated kinase activity div- 
ided by unstimulated activity and are mean + S.E.M. from three ex- 
periments. 
phorylation of the JNK  substrate c-Jun in a time-dependent 
fashion (Fig. 3C) and revealed a pattern that showed that 
JNK  phosphorylation paralleled JNK  activity. 
Furthermore, we investigated the effect of E2 on p38 phos- 
phorylation. In contrast, stimulation with E2 did not signifi- 
cantly influence p38 phosphorylation i cardiomyocytes from 
adult female rats as shown by Western blot analysis (Fig. 4A) 
and phosphorylation assay (Fig. 4B). Cotreatment with the 
ER antagonist ICI 182.780 (10 8 M) had no effect on p38 
phosphorylation and activation, but cotreatment with the spe- 
cific inhibitor of p38, SB 203580 (10 5 M), decreased activa- 
tion of p38. 
The response was specific to E2, because 17a-estradiol 
(10 9 M), known to be biologically ineffective as an estrogen, 
failed to alter the activation of ERK,  JNK  and p38 phosphor- 
ylation (data not shown). All experiments were repeated with 
lysates obtained from adult male rats revealing a similar effect 
of E2 on these signaling cascades which demonstrates a gen- 
der-independent phenomenon (data not shown). 
Termination of MAPK activity is regulated by MKP, which 
dephosphorylates and inactivates MAPK. The expression lev- 
el of MKP1 protein correlates with the kinetics of dephos- 
phorylation of MAPK. Since MKP1 is principally regulated 
at the transcriptional level, we studied MKP1 gene expression 
in cardiomyocytes in response to stimulation with E2 (Fig. 5). 
MKP1 protein expression increased after 30 rain stimulation 
with E2 and correlated with the kinetics of ERK1/2 dephos- 
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phorylation. MKPI  expression was completely inhibited by 
cotreatment with the ER antagonist ICI 182.780 (10 ~ M). 
Finally, we examined if estrogenic target genes such as the 
endothelial and inducible NO synthases (eNOS/iNOS) are 
regulated by estrogen via the MAPK pathway. Treatment of 
cardiomyocytes with E2 for 60 min (10 9 M) causes an in- 
crease of NOS expression (iNOS: 23.4+9.1-fold; eNOS: 
6.0_+ 1.6-fold). Coincubation with an inhibitor of the MAPK 
pathway, PD 98059. suppressed the upregulation of iNOS 
(Fig. 6A) and eNOS (Fig. 6B) in cardiomyocytes. These re- 
suits suggest hat eNOS and iNOS expression induced by E2 
is at least partially dependent on MAPK phosphorylation. 
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Fig. 3. Induction of JNK phosphorylation i  cardiomyocytes by E2. 
Cardiomyocytes obtained from adult female (A) and neonatal (B) 
cardiomyocytes were treated with E2 (10 -9 M) for the indicated 
time periods (5 120 rain). Total cellular lysates were subjected to 
SDS-PAGE, and immunoblotted with an antibody specifically de- 
tecting the phosphorylated JNK. Note that the phosphorylated pro- 
tein (pJNK) is detectable in the absence of E2 (Control, C). but is 
more abundant following treatment with E2. Coincubation with the 
antiestrogen ICI 182.780 (10 s M, 15 rain) inhibited the E2-medi- 
ated phosphorylation of JNK. C: JNK phosphorylation assay 
shows activation of JNK target protein c-Jun in a time-dependent 
fashion which paralleled JNK phosphorylation. 
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Fig. 4. p38 activity stimulated by E2. Adult female cardiomyocytes 
were stimulated with E2 (10 -9 M) for the indicated time periods (5 
120 min). Control cells were coincubated with the specific ER an- 
tagonist 1CI 182.780 (ICI, 10 -8 M, 15 rain) and with an specific in- 
hibitor of p38, SB 203580 (SB, 10 5 M, 15 rain). A: Phosphoryl- 
ation level of p38 was examined by Western blot analysis using an 
antibody specifically detecting the phosphorylated p38 protein. E2 
did not cause a significant al eration of p38 phosphorylation. B: In- 
fluence of E2 on p38-mediated phosphorylation of ATF2 as shown 
by phosphorylation assay. 
4. Discussion 
The role of estrogen in the pathogenesis of gender-based 
differences found in cardiac disease is currently under inves- 
tigation [1~,28]. The importance of hormonal regulation of 
cardiac disease is underlined by the observation that women 
tend to develop cardiac hypertrophy only after the onset of 
menopause. All the clinical sequelae of coronary artery dis- 
ease are worsened in patients with left ventricular hypertrophy 
in coincidence with an six-fold increase in sudden death [29]. 
Up to now most cellular effects of estrogen in the myocardium 
have been thought to be mediated by intracellular estrogen 
receptors that serve as ligand-induced transcription factors. 
In cardiomyocytes trogen activates downstream target genes 
such as connexin 43 or NO synthases via ERc~ and 13 [10,11]. 
Furthermore, rapid, therefore termed non-genomic, actions of 
[kDa] 
121 - 
79 -  
33- 
C 5 15 30 60 120 ICI 
- MKP1 
Fig. 5. Expression of MKPI in cardiomyocytes is induced by E2. 
Cardiomyocytes from neonatal rats were stimulated with E2 (10 9 
M) for the indicated time periods (5 120 min). Cell lysates were an- 
alyzed by Western blot analysis using an antibody against MKP1 
protein. E2-induced expression of MKP1 and cotreatment with ICI 
182.780 for 1 h inhibited E2-induced xpression of MKP1. 
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Fig. 6. Influence of ERK1/2 on E2-stimulated NO synthase expres- 
sion. Adult female cardiomyocytes were incubated with E2 (10 9 
M) for 1 h. Cell lysates were analyzed by Western blot analysis us- 
ing specific antibodies against eNOS (A) or iNOS (B). Cotreatment 
with the pure antiestrogen ICI 182.780 (ICI, 10 -s M, 1 h) and with 
the MAPK pathway inhibitor PD 98059 (PD, 10 .5 M, 1 h) inhib- 
ited upregulation of eNOS and iNOS expression. 
estrogen on the myocardium such as the modulation of the 
L-type calcium current in cardiac myocytes obtained from 
human, rat or guinea pig heart have been described [12,13]. 
These genomic and non-genomic effects of estrogen may well 
play an important role in the cellular control of cardiac 
hypertrophy. The exact mechanisms of non-genomic effects 
of estrogen on the myocardium, however, remain to be clari- 
fied. 
Here we show for the first time that E2 differentially acti- 
vates intracellular signaling pathways which are involved in 
regulatory processes leading to cardiac hypertrophy [30]. 
Treatment of cardiac myocytes with E2 results in a rapid 
time-dependent activation of ERK1/2 and JNK. ERK1/2 
and JNK activation occurred within 5-15 min, demonstrating 
that estrogen regulates non-genomic effects in cardiac myo- 
cytes. Interestingly, Migliaccio et al. [31] showed that the ac- 
tivation of the tyrosine-kinase/p21r~S/MAPK pathway in 
MCF-7 cells (mammary gland tumor cells) by estrogen re- 
quires the ligand occupancy of the estrogen receptor. We 
were able to demonstrate that the activity of ERK1/2 and 
JNK is completely inhibited by an ER-specific antagonist, 
indicating that the effect of E2 on ERKI/2 and JNK activity 
in cardiac myocytes is also mediated by the ER. Our findings 
raise a very intriguing question: how can the ER, which is 
usually known as a transcription factor, stimulate MAPK? A 
possible explanation is that the estrogen-ER complex may 
interact directly with signaling proteins. A second possible 
mechanism could involve the interaction between the ligand- 
activated ER and other peptide growth factors as shown re- 
cently by Karas et al. [32]. It is noteworthy that 17~-estradiol, 
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while activating ERK and JNK, does not significantly stim- 
ulate the p38 pathway, p38 has been suggested to playa major 
role in the regulation of myocardial cell hypertrophy [30,33]. 
While activation of JNK and ERK generated only modest 
increases in cell size and natriuretic and c~-skeletal ctin pro- 
moter activity, induction of p38 significantly augmented cell 
size and promoter activity [34]. The identification of novel 
regulatory kinases (MEKKs) upstream of the signaling cas- 
cades mentioned above may help to elucidate these findings 
[35]. Each of these MEKKs is associated with a distinct 
MAPK cascade. There is at least one MEKK, MEKK3, 
which contains the ability to simultaneously activate ERKI/  
2 and JNK, but not p38 [36]. This serves as a likely explan- 
ation why both pathways are targets of estrogen stimulation. 
As we demonstrate that E2 significantly stimulates ERK1/2 
and JNK but not p38, it is tempting to speculate whether 
estrogen only exerts a modest effect on mediators of cardiac 
myocyte hypertrophy such as the p38 pathway. 
Duration of MAPK activation by extracellular stimuli is 
critical for cell signaling outcomes [37]. Inactivation of 
MAPK is mediated, in part, by dephosphorylation of 
MAPK by dual-specificity phosphatases (MKPs) that dephos- 
phorylate both threonine and tyrosine residues phospho 2 
rylated by MEK [15]. Since MKP is principally regulated at 
the transcription level, we have studied cardiac MKP1 gene 
expression in response to estrogen. Estrogen-induced xpres- 
sion of MKP1 protein in cardiomyocytes correlates with the 
kinetics of dephosphorylation of MAPK. Furthermore, 
MKP1 expression was inhibited by ICI 182.780. Therefore, 
control of MAPK activity by E2 is exercised not only at the 
level of protein phosphorylation, but also through phospha- 
tases such as MKP1 at the level of dephosphorylation. Taken 
together, these data demonstrate hat 17[3-estradiol influences 
both phosphorylation and deactivation of these protein ki- 
nases and that this process is also mediated through the ER. 
Finally, we have studied the ffect of MAPK signaling on 
the regulation of estrogenic target genes. Recently, we have 
shown that E2 stimulates expression of eNOS and iNOS in rat 
myocardium in vitro and in vivo [11]. Here we show that 
upregulation of iNOS and eNOS by 1713-estradiol in cardio- 
myocytes is inhibited in the presence of an inhibitor of the 
MAPK pathway (PD 98059). Therefore, a prerequisite for the 
elevated expression of both eNOS and iNOS seems to be the 
activation of ERK1/2 by estrogen. 
In summary, we were able to demonstrate that estrogen 
activates ERK1/2 and JNK but not p38 in cardiac myocytes. 
Furthermore, 17[3-estradiol induces MKP1 in cardiac myo- 
cytes and MEK blocker inhibits estrogen-induced NO syn- 
thase expression. These observations may help to dissect he 
role of estrogen in the pathogenesis of gender-based differ- 
ences found in cardiac hypertrophy. 
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